Answers are grounded in this paper and cite their sources.
mu-tations in exon 2 could predict a lack of response in patients who received panitumumab plus oxali -platin, fluorouracil, and leucovorin (FOLFOX4) for the treatment of metastatic colorectal cancer. The grade of rash in patients who received an anti–epidermal growth factor receptor antibody has been strongly associated with clinical out-come, even in patients who have
No takes yet. Share an insight, caveat, or question.
A 2013 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: